Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

All Older AML Patients and Younger Patients with Adverse Biology Should Receive HMA/Venetoclax Instead of 3+7/Standard Induction

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Daniel Pollyea
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Daniel Pollyea
0 views
October 17, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
Acute Myeloid Leukemia
15:38
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

2019 AML State of the Art Update: How to Treat Newly Diagnosed and S…

Feat. S. Luger
16:27
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

CAR T-Cells in AML: An Effective Therapy Requires Optimization of th…

Feat. E. Budde
13:57
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Novel Strategies in High Risk AML: Clinical and Molecular Features

Feat. J. Welch
16:06
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Chemotherapy-Free Approach in Relapsed/Refractory AML: Antibody-Drug…

Feat. J. DiPersio
15:39
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

All Older AML Patients and Younger Patients with Adverse Biology Sho…

Feat. D. Pollyea
17:20
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

HMA/Ventoclax vs. 3+7/Standard Induction - Should All Older and Youn…

Feat. J. Lancet
15:19
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Use of MRD in AML: Determining Method, Acceptable Endpoint and Progn…

Feat. P. Montesinos
14:52
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

How to Choose a FLT3 inhibitor in AML in 2019: Discussion on Midosta…

Feat. C. Smith
15:52
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Use of Gemtuzumab in CD33 + AML: Benefit May Be Greatest in Favorabl…

Feat. R. Walter
08:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Synergistic Activity of the MCL-1 Inhibitor S63845 with Midostaurin …

Feat. A. Skwarska
09:44
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Promising Data on Efficacy of Mutant IDH1 Inhibitor Ivosidenib (…

Feat. C. DiNardo
08:59
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Genome-Wide CRISPR-Cas9 Screen Identifies XPO7 as a Novel Therapeuti…

Feat. Y. Semba